ABSTRACT
Mitochondrial dysfunction has long been associated with insulin resistance, yet the causal relationship in humans remains unresolved. Here, we leveraged individuals carrying the diabetogenic m.3243A>G mtDNA mutation as a human genetic model to probe the causal contribution of mitochondrial defects to insulin resistance and delineate the underlying molecular and bioenergetic mechanisms. In vivo metabolic phenotyping revealed selective skeletal muscle insulin resistance with preserved liver and adipose insulin sensitivity, accompanied by impaired glucose tolerance, β-cell dysfunction, and elevated circulating levels of the mitochondrial stress-responsive cytokine GDF15. At the molecular level, this muscle-specific insulin-resistant phenotype featured preserved insulin-stimulated Akt-TBC1D4 signaling but blunted mTORC1 activation. Integrated muscle proteomic and bioenergetic profiling demonstrated reduced mitochondrial protein abundance and complex I-specific molecular and functional impairments, alongside downregulation of non-mitochondrial metabolic proteins including AMPKγ2. In summary, our study establishes a mitochondrial basis for insulin resistance in humans, linking reduced mitochondrial content and complex I-related defects to disrupted mTORC1 signaling and impaired muscle insulin action. These findings highlight mitochondria-dependent molecular signatures of insulin resistance that may hold translational relevance for improving glucose regulation in common metabolic diseases.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a project grant from Fabrikant Vilhelm Pedersen og Hustrus Legat on the recommendation of the Novo Nordisk Foundation and by a PhD scholarship from the Research Council at Copenhagen University Hospital-Rigshospitalet.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Research Ethics Committee of the Capital Region of Denmark gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵9 Lead contact
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
